Johnson & Johnson (JNJ), the earnings bellwether for the healthcare sector, reported better-than-expected revenue for Q4 2025 on Tuesday thanks to its Pharma and MedTech divisions. However, the shares of the New Brunswick, New Jersey-based healthcare giant slipped ~2% in the premarket as its adjusted earnings for the quarter did not exceed the consensus.
“2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history,” CEO Joaquin Duato remarked ahead of the earnings call at 8:30 a.m. ET.
The company reported $24.6B in revenue for the quarter compared to $24.16B in the consensus, while its adjusted earnings for Q4 stood at $2.46 per share, in line with analysts’ expectations.
As for segmental performance, J&J’s (JNJ) Innovative Medicine and MedTech units added $15.8B and $8.8B to the topline, exceeding the $15.45B and $8.67B projected by analysts, respectively, according to Bloomberg data.
This is a developing story. Check back for more updates.